CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Long-term Cardiac Arrhythmias recorded by Insertable Loop.

Slides:



Advertisements
Similar presentations
Linoxsmart S DX Master Study
Advertisements

Prognostic significance of atrial fibrillation/flutter following acute myocardial infarction in patients with diabetes mellitus M.Gashi,E.Pllana,D.Kocinaj,S.Rexhepi.
The MADIT II Trial Multicenter Autonomic Defibrillator Implantation Trial II Presented at the American College of Cardiology 51st Annual Scientific Session.
ASSENCE Assessment of cost-effectiveness of Several Strategies of Early diagnosis in patients with acute chest pain and Non Conclusive Electrocardiogram.
Presenter Disclosure Information
Gentofte University Hospital
2/9/2014 The Prevalence and Prognostic Significance of ECG Abnormalities For: ECG in Ischemic Heart Disease By: V. Froelicher, MD Palo Alto VAHCS and Stanford.
EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Sudden Cardiac Death Prevention: Clinical Trials Alena Goldman, MD September 9, 2004.
Tobias Reichlin, W. Hochholzer, C. Stelzig, K. Laule, M. Potocki, K
Myocardial Ischemia: An Underrated Cause of Sudden Cardiac Death?
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT-RIT) Arthur J. Moss, MD for the MADIT-RIT Executive Committee AHA Late Breaking Trials November.
La stratificazione del rischio aritmico oltre la frazione di eiezione Milano 17 Aprile 2009 Prof. Luigi Padeletti Heart Failure & Co.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
CRT-D Effectiveness by QRS Duration and Morphology in the MADIT-CRT Patients Wojciech Zareba, MD, PhD, Helmut Klein, MD, Iwona Cygankiewicz, MD, PhD, W.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
COMMIT/CCS-2 (ClOpidogrel & Metoprolol in Myocardial Infarction Trial)
Arrhythmias: The Good, the Bad and the Ugly
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Sudden death as co-morbidity in patients following vascular intervention Sudden death as co-morbidity in patients following vascular intervention Impact.
Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.
Heartland Cardiology Dr. John Dongas The Beat Goes On: Biventricular Devices.
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Arrhythmia recognition and treatment
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
Massie I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Barry Massie and Peter Carson Executive Committee M. Komajda, R. McKelvie,
CRUSADE: A National Quality Improvement Initiative CRUSADE: A National Quality Improvement Initiative Can Rapid Risk Stratification of Unstable Angina.
Cardiac memory distinguishes between new and old left bundle branch block Alexei Shvilkin, MD, PhD.
Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,
Sudden Cardiac Death; Invasive Evaluation Alpay Çeliker MD Hacettepe University Department of Pediatric Cardiology Ankara, Türkiye.
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
Sex-Specific Chest Pain Characteristics in AMI Jay Mansfield, Pgy-3 July 22, 2014 LSU Journal Club Gimenez, M, et. Al. Jama Int Med. 2014;174(2):
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Introduction Left bundle branch block (LBBB) is notorious for obscuring the ECG diagnosis of acute myocardial infarction (AMI) and, therefore, the decision.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
EP show – June 2004 EP show The EP show: Risk stratification for sudden death Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent.
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
MICHELANGELO: OASIS 5 Women’s Substudy Dr. Eva Swahn Department of Cardiology, Heart Centre, University Hospital, Linköping Sweden Disclosure Funded by.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Risk Stratification in Unstable Angina Prospective Validation of the Braunwald Classification JAMA, January 11, 1995-Vol.273,No. 2.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Dr. Frank L.Y. Tam Queen Elizabeth Hospital Cardiology Division.
TAHAR EL KANDOUSSI, SARA ECHERKI, NAWAL DOGHMI, MOHAMED CHERTI. SEcurite de l’Echocardiographie de stress : plutôt l’effort. Cardiology B Department, Ibn.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Francisco F. Aviles, MD, PhD Hospital General Universitario (PI)Gregorio Marañon Madrid, Spain Emerson C. Perin, MD, PhDTexas Heart Institute (Co-PI)Houston,
Ventricular Arrhythmias:A General Cardiologist’s Assessment of Therapies in 2004 C.Richard Conti M.D. MACC.
Sudden Cardiac Arrest Morhaf Ibrahim, MD, FHRS Electrophysiology.
Risk Stratification of Chest Pain: Best Practices
Volume 8, Issue 3, Pages (March 2011)
. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.
The European Society of Cardiology Presented by Dr. Saman Rasoul
European Heart Association Journal 2007 April
Univ. of Copenhagen, Denmark
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
Infarct Size after Primary Angioplasty Patients With Bivalirudin
Presentation transcript:

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Long-term Cardiac Arrhythmias recorded by Insertable Loop Recorders in Patients with depressed Left Ventricular Function after Acute Myocardial Infarction Cardiac Arrhythmias and RIsk Stratification after Myocardial infArction PE Bloch Thomsen,MD,PhD Univ. of Copenhagen, Denmark geh.regionh.dk

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Disclosures Research grant and speaker fee Boston Scientific Guidant Medtronic BRC St. Jude Medical Sponsored by Medtronic Bakken Research Center Cambridge Heart Inc

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 CARISMA investigators Principal investigators: H. Huikuri, Finland, PE Bloch Thomsen, Denmark P. RaatikainenUniversity of Oulu, Finland R.M. JoergensenUniversity of Copenhagen, Denmark J. HartikainenUniversity of Kuopio, Finland V. VirtanenUniversity of Tampere, Finland J. BolandHopital Citadelle, Liège, Belgium O. AnttonenPaijat-Hame Hospital, Lahti, Finland L.A.V. BoersmaSt. Antonius Hospital, Nieuwegein, Netherlands E.S. PlatouUniversity of Oslo, Norway E. StoupelHopital Erasme, Brussels, Belgium J. Rokkedal, N. HoestAmtssygehuset Glostrup, Denmark European multicenter, prospective, observational study

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Assess the predictive value of electrophysiologic testing and non-invasive screening tests for life-threatening tachyarrhythmia performed at 6-weeks post-AMI CARISMA – Objective 1 (HRS, Hot Line Session May 10, 2007)

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 CARISMA – Objective 2 Document the incidence and assess the prognostic significance of cardiac arrhythmias obtained from an insertable ECG loop recorder

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Inclusion criteria Patients within 3 to 21 days of AMI + CKMB or Troponin elevation + Typical chest pain or ECG changes EF < 40%, 2-D echo ( WMI < 1.3) Planned CABG/ ICD NYHA IV Informed consent not obtained Exclusion criteria

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Study design 312 pts informed consent 1393 (24%) EF < 40% 5869 pts with AMI ILR implantation 297 pts 5-21 days post-MI 3-21 days post-MI Quarterly follow-up 2 year post-MI

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Implantable loop recorder Weight 17 g. Longevity up to 2 years. ECG storage 42 min, automatic detection algorithms sampling rate 100 Hz

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Patient characteristics enroll: 2002 to 2005 Baseline # of pts312 Gender (men)77% Age (years)65  11 LVEF31%  6 AF permanent9% QRS > 120 ms15% Diabetes 20% Prior MI 37% Hx of CHF (II-III)11% Revascularization Primary PCI30% Thrombolysis35% Rx at discharge ASA90% Beta-blockers96% ACE / AT II89% Statins82%

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Definitions: p re-specified arrhythmia Sinus bradycardia≤ 30 bpm, > 8s Sinus arrest≥ 5s AV block (2°, 3°)≤ 30 bpm, > 8s Non-sustained VT ≥ 125 bpm, ≥16 beats Sustained VT ≥ 125 bpm, ≥ 30 s New Onset Atrial Fib ≥ 125 bpm

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Incidence of pre-specified arrhythmias recorded by the ILR Mean follow-up 1.9 years 137 pts (46%) documented either VF or at least one pre-specified arrhythmias 86% were asymptomatic

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Bradyarrhythmia: Time to first arrhythmia by ILR Sinus arrest (>5s) n=16 (5%) Sinus brady (>8s) n=20 (7%) AV block (>8s) n=29 (10%)

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008

Tachyarrhythmia: Time to first arrhythmia by ILR Ventricular Fib. n=8 3% VT Sust. n=9 3% VT Non-sust. n=39 13% Atrial Fib n=95 32%

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008

Univariate Analysis predictors of Cardiac Death p-ValueHazardArrhythmia Ratio AV block < 30 bpm* Sinus brady < 30 bpm Non sustained VT * AV block also independent predictor

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Conclusion Incidence of arrhythmias Mean follow up 1.9 years 32% had new onset atrial fibrillation 20% had (2°or 3°) AV block or sinus brady 13% had non sust VT 11% had sust VT/VF

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Conclusion AV block is an independent predictor of cardiac death

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Conclusion The ILR is a strong diagnostic tool and should be considered in future studies for improved management of our patients

CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008